- 文献引用 : 1
|Application ||WB, E|
|Other Names||Cyclin-dependent kinase inhibitor 1, CDK-interacting protein 1, Melanoma differentiation-associated protein 6, MDA-6, p21, CDKN1A, CAP20, CDKN1, CIP1, MDA6, PIC1, SDI1, WAF1|
|Target/Specificity||This CDKN1A antibody is generated from mice immunized with a KLH conjugated synthetic peptide between 117-146 amino acids from the C-terminal region of human CDKN1A.|
|Format||Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||CDKN1A Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Synonyms||CAP20, CDKN1, CIP1, MDA6, PIC1, SDI1, WA|
|Function||May be involved in p53/TP53 mediated inhibition of cellular proliferation in response to DNA damage. Binds to and inhibits cyclin-dependent kinase activity, preventing phosphorylation of critical cyclin-dependent kinase substrates and blocking cell cycle progression. Functions in the nuclear localization and assembly of cyclin D-CDK4 complex and promotes its kinase activity towards RB1. At higher stoichiometric ratios, inhibits the kinase activity of the cyclin D-CDK4 complex. Inhibits DNA synthesis by DNA polymerase delta by competing with POLD3 for PCNA binding (PubMed:11595739).|
|Cellular Location||Cytoplasm. Nucleus.|
|Tissue Location||Expressed in all adult tissues, with 5-fold lower levels observed in the brain|
Author : Wu Z1, Liu K2, Wang Y2, Xu Z2, Meng J2, Gu S2.
Cancer Cell Int. 2015 Nov 14;15:107.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen (PCNA), a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of CDK2, and may be instrumental in the execution of apoptosis following caspase activation. Multiple alternatively spliced variants have been found for this gene.
Hu, F., et al. Oncogene 29(40):5464-5474(2010)
Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)
Jiang, P., et al. Acta Biochim. Biophys. Sin. (Shanghai) 42(9):671-676(2010)
Ho-Pun-Cheung, A., et al. Pharmacogenomics J. (2010) In press :
Do Nascimento Borges, B., et al. In Vivo 24(4):579-582(2010)